Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma

Immune checkpoint inhibitors (ICI) can induce atypical tumor responses including pseudoprogression in a subset of patients who may benefit from treatment beyond progression. While ICIs have emerged as frontline treatments for hepatocellular carcinoma (HCC) and are associated with clinical benefit in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Mir, Muquith, Maishara, Miramontes, Bernadette, Espinoza, Magdalena, Hsiehchen, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512891/
https://www.ncbi.nlm.nih.gov/pubmed/37772995
http://dx.doi.org/10.1158/2767-9764.CRC-23-0025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512891/
https://www.ncbi.nlm.nih.gov/pubmed/37772995
http://dx.doi.org/10.1158/2767-9764.CRC-23-0025

Ejemplares similares